WEST BATH — Scott Upham has been a part Trek Across Maine, a weekendlong cycling fundraiser for the American Lung Association, five times in the past, but in recent years, he was unsure if he would continue to ride.
All that changed when Scott Hamill, a friend and coworker who some describe as an athlete, was diagnosed with stage 4 lung cancer.
In early 2012, doctors thought Hamill simply suffered from chronic bronchitis until a chest x-ray revealed one lung had a massive cancerous nodule and the other, several smaller ones.
Hamill immediately began a new drug treatment. The size of the growths on Hamill’s lungs have since shrunken significantly, with doctors recently decreasing his dosage by more than half.
Upham’s team, previously riding in the trek as Russell Investments, came to be known as Team Scott Hamill.
“When I got the news about Scott, I felt powerless. I knew this was something that I could do,” Upham said.
Collectively, Team Scott Hamill raised more than $45,000, due in large part to the overwhelming support of Russell Investments, where Upham and Hamill worked together, according to a news release.
The team ranked fourth in fundraising among all corporate teams in 2012.
For more information about Trek Across Maine 2013, visit www.biketreknewengland.org.
Comments are not available on this story. Read more about why we allow commenting on some stories and not on others.
We believe it's important to offer commenting on certain stories as a benefit to our readers. At its best, our comments sections can be a productive platform for readers to engage with our journalism, offer thoughts on coverage and issues, and drive conversation in a respectful, solutions-based way. It's a form of open discourse that can be useful to our community, public officials, journalists and others.
We do not enable comments on everything — exceptions include most crime stories, and coverage involving personal tragedy or sensitive issues that invite personal attacks instead of thoughtful discussion.
You can read more here about our commenting policy and terms of use. More information is also found on our FAQs.
Show less